Table 3 Factors predictive of clinical relapse after entecavir or TAF cessation for all patients
Variables | Comparison | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||
Age (years) | Increase per one year | 1.019 (0.985–1.054) | 0.279 | ||
Gender | Male vs. female | 0.486 (0.240–0.983) | 0.045 | ||
Use of Rituximab | Yes vs. no | 4.469 (2.057–9.710) |  < 0.001 | 9.831 (4.007–24.121) |  < 0.001 |
Use of steroid | Yes vs. no | 2.903 (1.190–7.079) | 0.019 | ||
Use of anthracycline | Yes vs. no | 0.779 (0.359–1.691) | 0.527 | ||
Hematologic malignancy | Yes vs. no | 4.525 (2.128–9.639) |  < 0.001 | ||
Distant metastasis | Yes vs. no | 1.368 (0.561–3.334) | 0.491 | ||
NA therapy | TAF vs. entecavir | 1.505 (1.053–2.150) | 0.025 | 2.114 (1.415–3.158) |  < 0.001 |
AST (U/L) | Increase per one U/L | 1.007 (1.004–1.010) |  < 0.001 | ||
ALT (U/L) | Increase per one U/L | 1.004 (1.003–1.006) |  < 0.001 | ||
Total bilirubin | Increase per one mg/dL | 1.668 (0.788–3.527) | 0.181 | ||
Platelet × 103/μL | Increase per 103/μL | 0.993 (0.988–3.527) | 0.014 | ||
FIB-4 | Increase per ratio | 1.770 (1.429–2.193) |  < 0.001 | 1.970 (1.557–2.492) |  < 0.001 |
Viremia groups* |  < 0.001 |  < 0.001 | |||
Low-viremia group | Reference | Reference | |||
Moderate-viremia group | 1.230 (0.307–4.920) | 0.770 | 1.299 (0.318–5.299) | 0.715 | |
High-viremia group | 6.091 (1.823–20.352) | 0.003 | 7.259 (2.075–25.401) | 0.002 | |
HBsAg level at EOT (IU/mL)** | Increase per one log IU/mL | 2.050 (1.384–3.038) |  < 0.001 | ||
Treatment duration | Increase per one week | 1.002 (0.988–1.017) | 0.771 | ||
Consolidation duration | Increase per one week | 0.977 (0.941–1.013) | 0.221 | ||